taplucanium dry powder inhaler (NOC-110) / Nocion Therap - LARVOL DELTA

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=455 | Active, not recruiting | Sponsor: Nocion Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough (Businesswire) - "The financing extends the Company’s operating runway through 2027, beyond the expected topline results from Nocion’s ASPIRE Phase 2b clinical trial of taplucainium in adults with refractory or unexplained chronic cough (rCC/uCC), which are expected in mid-2026....Proceeds will support the development of taplucainium dry powder for inhalation for the treatment of chronic cough beyond the ASPIRE study towards later-stage activities such as an End-of-Phase 2 meeting and CMC activities in preparation for later-stage clinical development....The ASPIRE Phase 2b clinical trial is currently enrolling at sites in the U.S., Canada, the U.K., and Europe."

Financing • P2b data • Trial status • Chronic Cough

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=455 | Recruiting | Sponsor: Nocion Therapeutics | Trial completion date: Nov 2025 ➔ Apr 2026 | Trial primary completion date: Nov 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=455 | Recruiting | Sponsor: Nocion Therapeutics | N=325 ➔ 455

Enrollment change • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study (Businesswire) - "Nocion Therapeutics...today announced that the first patient has been dosed in the Phase 2b ASPIRE clinical trial of taplucainium for the treatment of chronic cough.... Approximately 325 patients will be enrolled in the study at over 100 sites across the US, Canada, UK and Europe."

Trial status • Chronic Cough

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=325 | Recruiting | Sponsor: Nocion Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=325 | Not yet recruiting | Sponsor: Nocion Therapeutics | N=240 ➔ 325

Enrollment change • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

ASPIRE: Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Nocion Therapeutics

New P2 trial • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Nocion Therapeutics Presents Data on Preclinical and Clinical Development of Taplucainium, a Novel, Charged Sodium Channel Blocker, as a potential treatment for Chronic Cough at the 13th London International Cough Symposium (Businesswire) - "Nocion Therapeutics...today announced the presentation of progress in the development of taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium....'We look forward to the start of our ASPIRE (Phase 2b) clinical trial of taplucainium in 240 chronic cough patients in the second half of 2024.'...The broader mechanism of taplucainium has shown significant antitussive effects in preclinical models of cough. Combined with good preliminary safety and efficacy data from earlier stage clinical work, this forms the basis for its investigation not just in chronic cough but in other cough indications as well."

New P2b trial • Preclinical • Chronic Cough

Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment (ACCESSWIRE) - "Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics...These innovative compounds are designed to selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.....'This robust raise will allow for a comprehensive evaluation of Taplucanium in Chronic Cough patients, and completion of additional activities to advance this program to Phase 3 readines...'"

Financing • Chronic Cough